Madiha Iqbal, MBBS

Madiha Iqbal practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Madiha Iqbal's NPI, 1649687518, was assigned on July 12, 2014. Madiha Iqbal graduated from Fatima Jinnah Medical College in 2011. Madiha Iqbal holds Florida license ME132180.

Madiha Iqbal's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Madiha Iqbal's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Madiha Iqbal practices. Vendor and product names are available with a free account.

Hematology and oncology is Madiha Iqbal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Madiha Iqbal is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Madiha Iqbal's licenses on file in 2 states: Florida and Oklahoma.

Dmand AI lists breast cancer, chronic leukemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Madiha Iqbal treats.

CMS data shows 30,472 Medicare services from Madiha Iqbal across 43 procedure codes in 2024, for 513 Medicare patients. Medicare paid $598,279 for them.

CMS counts 513 Medicare patients who saw Madiha Iqbal in 2024. The largest group is 65 to 74, with 263 patients. 73% of them have high blood pressure, and 73% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Madiha Iqbal's median patient age at 63, with 50% women.

In 2024, Madiha Iqbal wrote 248 Medicare Part D claims for 48 patients. 79% of them were for generic drugs. CMS names the drug for 163 of them, across 8 drugs with 11 or more claims each, at $290,615 in total drug cost. In 2023, CMS named 143 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Madiha Iqbal for performance year 2024, reported as part of a group. Madiha Iqbal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Madiha Iqbal as offering telehealth.

Dmand AI links 86 papers to Madiha Iqbal, published from 2018 to 2025. 2023 was the busiest year, with 14. The most frequent topics are Immunotherapy, Adoptive, Hematopoietic Stem Cell Transplantation and Receptors, Chimeric Antigen. Madiha Iqbal has published most often in Blood Adv. Madiha Iqbal's most frequent co-authors are Hemant Sreenivasa Murthy, MD, Ernesto Ayala, MD and Allison C. Rosenthal, DO.

Dmand AI links Madiha Iqbal to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Precursor B-Cell Lymphoblastic Leukemia-Lymphoma and Leukemia, Lymphocytic, Chronic, B-Cell.

CMS Open Payments shows 90 general payments to Madiha Iqbal from 23 drug and device companies from 2018 to 2025. Honoraria make up the largest share, 37% of the total. ADC Therapeutics America, Inc. paid the most, $13,372.

Dmand AI lists 1 award for Madiha Iqbal, most recently Second position in Sarcoma Super Bowel in 2017.

Madiha Iqbal graduated from Fatima Jinnah Medical College in 2011.

Madiha Iqbal is in network with 6 carriers, including Elevance, United Healthcare and Aspirus Health Plan. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.